Terms: = Ovarian cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP
250 results:
1. HER2-low and Overexpression in Mucinous ovarian cancer: Analysis of ASCO/cap and ToGA Immunohistochemical Scoring.
Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
[TBL] [Abstract] [Full Text] [Related]
2. Methylation of brd4 by PRMT1 regulates brd4 phosphorylation and promotes ovarian cancer invasion.
Liu Y; Liu H; Ye M; Jiang M; Chen X; Song G; Ji H; Wang ZW; Zhu X
Cell Death Dis; 2023 Sep; 14(9):624. PubMed ID: 37737256
[TBL] [Abstract] [Full Text] [Related]
3. Bromodomain-containing protein 4 activates androgen receptor transcription and promotes ovarian fibrosis in PCOS.
Wang D; Zhu Z; Fu Y; Zhang Q; Zhang Y; Wang T; Weng Y; Wen Y; Cao W; Tao G; Wang Y
Cell Rep; 2023 Sep; 42(9):113090. PubMed ID: 37669164
[TBL] [Abstract] [Full Text] [Related]
4. HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
[TBL] [Abstract] [Full Text] [Related]
5. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
6. Arterial events in cancer patients treated with apixaban for venous thrombosis.
Larsen TL; Svalastoga M; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2023 Aug; 228():128-133. PubMed ID: 37327527
[TBL] [Abstract] [Full Text] [Related]
7. Gynecological cancer prognosis using machine learning techniques: A systematic review of the last three decades (1990-2022).
Sheehy J; Rutledge H; Acharya UR; Loh HW; Gururajan R; Tao X; Zhou X; Li Y; Gurney T; Kondalsamy-Chennakesavan S
Artif Intell Med; 2023 May; 139():102536. PubMed ID: 37100507
[TBL] [Abstract] [Full Text] [Related]
8. brd4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
[TBL] [Abstract] [Full Text] [Related]
9. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells.
Quintela M; James DW; Pociute A; Powell L; Edwards K; Coombes Z; Garcia J; Garton N; Das N; Lutchman-Singh K; Margarit L; Beynon AL; Rioja I; Prinjha RK; Harker NR; Gonzalez D; Conlan RS; Francis LW
Clin Epigenetics; 2023 Apr; 15(1):63. PubMed ID: 37060086
[TBL] [Abstract] [Full Text] [Related]
10. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce SF; Wu S; Ribeiro JR; Farrell A; Oberley MJ; Winer I; Erickson BK; Klc T; Jones NL; Thaker PH; Powell MA
Gynecol Oncol; 2023 May; 172():98-105. PubMed ID: 37003074
[TBL] [Abstract] [Full Text] [Related]
11. Oleic acid stimulates cell proliferation and brd4-L-MYC-dependent glucose transporter transcription through PPARα activation in ovarian cancer cells.
Kado T; Kusakari N; Tamaki T; Murota K; Tsujiuchi T; Fukushima N
Biochem Biophys Res Commun; 2023 May; 657():24-34. PubMed ID: 36965420
[TBL] [Abstract] [Full Text] [Related]
12. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
[TBL] [Abstract] [Full Text] [Related]
13. Synergistic effect of PARP inhibitor and brd4 inhibitor in multiple models of ovarian cancer.
Huang Y; Liu C; You L; Li X; Chen G; Fan J
J Cell Mol Med; 2023 Mar; 27(5):634-649. PubMed ID: 36753396
[TBL] [Abstract] [Full Text] [Related]
14.
Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
[No Abstract] [Full Text] [Related]
15. Novel Approaches for the Solid-Phase Synthesis of Dihydroquinazoline-2(1
Wang Q; Pan Y; Luo H; Zhang Y; Gao F; Wang J; Zheng J
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500678
[TBL] [Abstract] [Full Text] [Related]
16. Design, synthesis and anti-ovarian cancer activities of thieno[2,3-d]pyrimidine based chimeric brd4 inhibitor/nitric oxide-donator.
Zhang Y; Pan Z; Chen C; Tan Y; Wang X; Wang L; Zhang L; Chen Y; He G
Eur J Med Chem; 2023 Jan; 246():114970. PubMed ID: 36470106
[TBL] [Abstract] [Full Text] [Related]
17. Imaging in gynecological disease (24): clinical and ultrasound characteristics of ovarian mature cystic teratomas.
Heremans R; Valentin L; Sladkevicius P; Timmerman S; Moro F; Van Holsbeke C; Epstein E; Testa AC; Timmerman D; Froyman W
Ultrasound Obstet Gynecol; 2022 Oct; 60(4):549-558. PubMed ID: 35316568
[TBL] [Abstract] [Full Text] [Related]
18. Reactivity of NK Cells Against ovarian cancer Cells Is Maintained in the Presence of Calcium Phosphate Nanoparticles.
Hrvat A; Schmidt M; Obholzer M; Benders S; Kollenda S; Horn PA; Epple M; Brandau S; Mallmann-Gottschalk N
Front Immunol; 2022; 13():830938. PubMed ID: 35251021
[TBL] [Abstract] [Full Text] [Related]
19. Comparing the 2017 ASCO/cap guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/cap guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma.
Chao WR; Lee MY; Lee YJ; Sheu GT; Han CP
Virchows Arch; 2022 May; 480(5):1023-1030. PubMed ID: 35226147
[TBL] [Abstract] [Full Text] [Related]
20. AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
Liu C; Huang Y; Qin T; You L; Lu F; Hu D; Xiao R; Qin X; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Zhang L; Cui Y; Sun C; Chen G
Cancer Lett; 2022 Mar; 528():31-44. PubMed ID: 34942306
[TBL] [Abstract] [Full Text] [Related]
[Next]
